About The Section
Publishes original research articles, letters, reviews/mini-reviews and guest-edited thematic issues on various topics related to enzymology.
This section is not limited to a specific aspect of the field but is instead devoted to a wide range of subfields in the area. Articles of a multidisciplinary nature are particularly welcome. Submissions in the following areas related to enzymology are of special interest to the readers of this journal:
• Biochemical- or biophysical-based assays
• Catalytic features and mechanisms
• Directed evolution of enzymes
• Enzyme expression profile
• Enzyme identification
• Enzyme immobilization strategies
• Enzyme ligands (Inhibitors, Inducers, Activators, Degraders)
• Enzyme products
• Enzyme properties
• Enzyme recombinant expression
• Enzyme single nucleotide polymorphism
• Enzyme species variation
• Enzyme subcellular localization,
• Enzyme substrates and metabolites
• Enzyme-based biosensors
• Enzyme-based biosynthesis
• Enzyme-related databases
• Enzyme-related diseases
• Enzyme-related techniques (Fermentation, Expression & purification, Enzyme mutation)
• Imaging of target enzyme in complex biological systems
• Physiological functions
• Relating signal pathways
• Structural and biochemical properties
Guang-Bo Ge received his Ph.D. degree in biochemical engineering in 2009 from Dalian Institute of Chemical Physics, Chinese Academy of Sciences. Currently, he is a full professor at the Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine. His research interests are focused on the development of the specific ligands for target enzymes and their biomedical applications. Now he is the author/coauthor of more than 230 publications in scientific journals.
Professor Wen-Lian Chen, Ph.D., is a scientist in the field of fundamental and translational studies of human cancers. By using multi-omics and molecular biology approaches, he aims to unravel the key metabolic pathways involved in cancer development and progression, and to identify new metabolic inhibitors with therapeutic potential for cancer therapy.
Professor Dai used chemoproteomics, biochemistry, molecular biology and other technologies to deeply reveal the pharmacodynamic molecular mechanism of natural products. Specifically, Professor Dai tried to establish the following methods: 1) through the chemical proteomics technology based on active probes, the direct target of natural products was found; 2) To establish a quantitative enzyme activity detection method, and accurately explore the regulatory effect of active molecules of traditional Chinese medicine on its target protein; 3) The interaction mechanism between active molecules and target proteins is elaborated by biophysics and bioinformatics, and the small molecule protein interaction sites are described by auxiliary molecular docking technology.
Tongyi Dou received his B.S. in Pharmaceutical Engineering from Tianjin University in 2009 and Ph.D. in Biochemical Engineering from University of the Chinese Academy of Sciences in 2016. He then joined Dalian University of Technology as an assistant professor. In 2018, he joined Dr. Jiansen Jiang's lab at NIH as a visiting scholar, working on membrane protein and Cryogenic electron microscopy (cryo-EM), as a member of the Biophysical Society. He has published over 43 research papers. Dr. Dou's research interests lie primarily in the function-structure relationship, and the protein-ligand interactions of drug ADME-related enzymes utilizing biochemistry, computational, and biophysics methodologies, with transporters SLC22 as the current focus.
Qing Ji, Doctor of Medicine, Research Fellow. He has long been devoted to the molecular mechanism of tumor microenvironment regulating tumor metastasis and the mechanism of traditional Chinese medicine intervention. He has published more than 130 papers in many excellent journals including Nat Commun, J Exp Clin Cancer Res, Cell Death Dis, Br J Cancer, Phytomedicine, Front Pharmacol, Front Immunol, etc.
Zhu Liangliang received his Ph.D. degree in Biochemical Engineering from Dalian Institute of Chemical Physics in 2013. He is now serving as an Associate Professor at the School of life science, Anqing Normal University, China. His research interests focus on modeling enzyme kinetics, development of new probing substrates, drug-drug interactions in metabolism, and synergistic effects of multi enzyme modulators. He has published more than 40 papers in reputed international journals.
Hua Sun is now an associate professor of School of Pharmacy, Henan University, China. She received her Ph.D from Jinan University (Guangzhou) in 2016. Dr. Sun's research is primarily based on drug metabolism and transport, mechanisms and factors that affect expression and regulation of drug-metabolizing enzymes and transporters, and anticancer pharmacology of natural products. She authored or co-authored over 30 papers in peer-review journals, including Drug Metab Dispos, Biochem Pharmacol, J Agric Food Chem, and Eur J Pharm Sci. etc.
Ping Wang received his Ph.D. degree in biochemistry and molecular biology (successive bachelor-doctor program) in 2012 from Northeast Agricultural University. From 2014 to 2017, he was a postdoctoral fellow at Dalian Institute of Chemical Physics, Chinese Academy of Sciences. Currently, he is an associate professor at Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine . His research interests focus on the development of inhibitors and biosensors of enzymes, and their biomedical applications.
Dr. Dewei Ye obtained his PHD degree from The University of Hong Kong in 2011. Afterwards, he worked as post-doctoral fellow in the Department of Medicine and State Key Laboratory of Pharmaceutical Biotechnology, the University of Hong Kong. In 2016, he joined the Guangdong Pharmaceutical University. Dr. Ye's research interest focuses on the investigation of mechanisms underlying the pathogenesis of obesity-related metabolic disorders, especially the pathophysiological roles of novel mediators for the development of metabolic inflammation in the liver and mechanisms underlying disease progression in the context Chinese Medicine. He identified the crosstalk between macrophages and neutrophils as one of the mechanisms corresponding to the development of nonalcoholic steatohepatitis, a clinically significant condition characterized by the evident metabolic inflammation in the liver. In addition, Dr. Ye found fibroblast growth factor 21 as a potential target for drug-induced acute liver injury in mice, which can protect mice through enhancing the antibiotic capacity in the liver. Dr. Ye has published original research papers in top-ranked peer-reviewed journals, including GUT, Hepatology, and Journal of Hepatology.
Da-Peng Chen received his Ph.D. degree in Biochemistry and molecular biology in 2014 from Dalian Medical University. Currently, he is an associate professor at Dalian Medical University. He is considered an expert of screening/developing small molecular drug targeting enzymes and their pharmacological effects.